Progesterone Receptor Negative Recruiting Phase 2 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03872388Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyTreatment